However, only cisplatin combined with pemetrexed showed significant differences in clinical outcome among the multiple cytotoxic treatments for advanced NSCLC patients.1, 16 In this study, we combined cisplatin with other new pathway inhibitors, mTOR and HDAC inhibitors, to treat NSCLC cancer cells. This evidence concerns the gene MTOR and non-small cell lung carcinoma.